Mereo BioPharma Group (Mereo BioPharma Group) Current Accrued Expense : $5.09 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Current Accrued Expense?

Mereo BioPharma Group's Current Accrued Expense for the quarter that ended in Dec. 2023 was $5.09 Mil.

Mereo BioPharma Group's quarterly Current Accrued Expense increased from Dec. 2022 ($5.44 Mil) to Jun. 2023 ($6.04 Mil) but then declined from Jun. 2023 ($6.04 Mil) to Dec. 2023 ($5.09 Mil).

Mereo BioPharma Group's annual Current Accrued Expense increased from Dec. 2021 ($5.16 Mil) to Dec. 2022 ($5.44 Mil) but then declined from Dec. 2022 ($5.44 Mil) to Dec. 2023 ($5.09 Mil).

Mereo BioPharma Group Current Accrued Expense Historical Data

The historical data trend for Mereo BioPharma Group's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Current Accrued Expense Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

6.74

5.69

5.16

5.44

5.09

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial												5.16	6.17	5.44	6.04	5.09

Mereo BioPharma Group Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Mereo BioPharma Group Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.